BeyondSpring BYSI
NASDAQ BYSI
$0.72 +0.00 (+0.00%)
At close: Aug 21, 2026 · 4:00 PM EDT

BeyondSpring (BYSI) Non-Current Deffered Revenue (2020 - 2026)

BeyondSpring (BYSI) posted Non-Current Deffered Revenue of $29.0 million for Q1 2026, up 1.38% sequentially from $28.6 million in Q4 2025, and up 5.2% YoY from $27.6 million in Q1 2025.

BeyondSpring (BYSI) Non-Current Deffered Revenue (2020 - 2026) Analysis & Trends

BeyondSpring has reported Non-Current Deffered Revenue for 7 years, with the latest figure at $29.0 million in Q1 2026.

  • Quarterly Non-Current Deffered Revenue rose 5.2% year-over-year to $29.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $29.0 million (up 5.2% YoY) and the FY2025 annual result came in at $28.6 million, up 4.38% from the prior year.
  • Non-Current Deffered Revenue improved to $29.0 million in Q1 2026 per BYSI's latest filing, from $28.6 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $35.8 million in Q2 2022 and troughed at $27.4 million in Q4 2024.
  • A 5-year average of $30.2 million and a median of $28.6 million in 2025 frame the typical range for Non-Current Deffered Revenue.
  • The sharpest annual moves came in 2022 and 2023: Non-Current Deffered Revenue surged 393.28% in 2022, then slipped 17.68% in 2023.
  • Over 5 years, Non-Current Deffered Revenue stood at $34.2 million in 2022, then retreated by 17.68% to $28.2 million in 2023, then dropped by 2.73% to $27.4 million in 2024, then climbed by 4.38% to $28.6 million in 2025, then rose by 1.38% to $29.0 million in 2026.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $29.0 million, $28.6 million, and $28.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn 220.40 Mn
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn 147.00 Mn
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn -
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 BeyondSpring 29.85 Mn 29.85 Mn - 29.48 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 29.48 Mn
Mar 31, 2026 28.99 Mn
Dec 31, 2025 28.60 Mn
Sep 30, 2025 28.09 Mn
Jun 30, 2025 27.92 Mn
Mar 31, 2025 27.56 Mn
Dec 31, 2024 27.40 Mn
Jun 30, 2024 32.34 Mn
Dec 31, 2023 28.17 Mn
Jun 30, 2023 33.53 Mn
Dec 31, 2022 34.22 Mn
Jun 30, 2022 35.76 Mn
Dec 31, 2021 37.94 Mn
Sep 30, 2021 37.77 Mn
Jun 30, 2021 7.25 Mn
Mar 31, 2021 7.59 Mn
Dec 31, 2020 7.93 Mn